TAVR Challenges | Explore Edwards Lifesciences' strategies to navigate slowing growth in its core TAVR business amid hospital workflow issues and increased competition |
TMTT Growth Potential | Delve into the company's thriving Transcatheter Mitral and Tricuspid Therapies segment, poised to become a significant revenue drive |
Strategic Acquisitions | Learn how recent $1.1 billion acquisitions of JenaValve and Endotronix could pave the way for Edwards Lifesciences' return to double-digit growth |
Financial Outlook | Analysts project EPS of $2.53-$2.60 for FY2025, with price targets ranging from $60 to $90, reflecting varied views on the company's growth prospects |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Metrics to compare | EW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWPeersSector | |
---|---|---|---|---|
P/E Ratio | 26.7x | −6.5x | −0.6x | |
PEG Ratio | 3.46 | −0.18 | 0.00 | |
Price/Book | 5.5x | 3.7x | 2.6x | |
Price / LTM Sales | 6.6x | 2.7x | 3.2x | |
Upside (Analyst Target) | 10.1% | 15.7% | 44.2% | |
Fair Value Upside | Unlock | −14.6% | 7.9% | Unlock |